drugset / Trial / NCT05447234
TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy
Phase 0
Not yet recruiting
50 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
TCRx Therapeutics Co.Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
To observe and determine the safety, tolerability, cellular pharmacokinetics and efficacy of TCRx T cells in patients with advanced or recurrent gastric/gastroesophageal junction cancer after failure of first chemotherapy.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2026-03-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tcrx T cell | Cell therapy | 1e+07 unknown | Intravenous |
| Subject | Tcrx T cell | Cell therapy | 3e+07 unknown | Intravenous |
| Subject | Tcrx T cell | Cell therapy | 1e+08 unknown | Intravenous |
| Subject | Tcrx T cell | Cell therapy | 3e+08 unknown | Intravenous |
| Subject | Tcrx T cell | Cell therapy | 1e+09 unknown | Intravenous |